The abstract is read at the publisher; the summary is JClub's.
Depleting CCR8 regulatory T cells overcomes resistance to immune checkpoint blockade in an isogenic immunocompetent model of BRCA2-deficient prostate cancer.
- Why it matters: BRCA2-mutated prostate cancer is aggressive and genomically unstable, but how this instability shapes tumor immune suppression and checkpoint therapy failure is unclear.
- What they did: In an isogenic immunocompetent Brca2-deficient prostate cancer model, BRCA2 loss activated cGAS/STING and type I interferon signaling, enriching Ccl8-expressing macrophages and CCR8 Tregs; anti-PD-1 expanded CCR8 Tregs.
- The result: CCR8 Treg depletion restored checkpoint blockade responsiveness, and human BRCA2-mutated prostate cancer samples showed elevated CCR8 expression, supporting CCR8 Tregs as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.